Autoimmune Encephalitis.

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Autoimmune encephalitis is more common than infectious encephalitis and presents as treatable neurologic syndromes.
• Early immunotherapy is crucial for optimal outcomes in autoimmune encephalitis.
• Antibodies targeting central nervous system proteins, such as LGI1, NMDA receptors, CASPR2, and GAD65, define specific autoimmune encephalitis syndromes.

Purpose of the Study:

• To outline the clinical features and diagnostic evaluations for identifying antibody-defined autoimmune encephalitis.
• To emphasize the importance of a clinically driven approach for diagnosing autoimmune encephalitis.
• To guide the rationale for immunotherapy administration based on clinical and serologic findings.

Main Methods:

• A clinically driven approach utilizing patient demographics, seizures, cognitive impairment, psychiatric disturbances, movement disorders, and peripheral features.
• Serologic testing for specific antibodies (e.g., LGI1, NMDA receptor, CASPR2, GAD65).
• Selective paraclinical testing and panel-based antibody testing.

Main Results:

• Distinct clinical features associated with specific antibodies aid in differentiating autoimmune encephalitis syndromes.
• Immunotherapy, guided by clinical-serologic findings, typically leads to some clinical improvement.
• Despite treatment, most patients experience residual neuropsychiatric deficits, and many have relapses.

Conclusions:

• A clinically driven approach combined with antibody testing is feasible for diagnosing autoimmune encephalitis.
• Early and expert-guided immunotherapy is essential for managing autoimmune encephalitis.
• Further research into pathophysiology and clinical trials are needed to address unmet medical needs and improve patient outcomes.